Potential "first-in-class" therapy for treating atopic dermatitis obtained clinical proof of concept

On September 27, 2021, ASLAN Pharmaceuticals announced that the monoclonal antibody ASLAN004, which targets the IL-13 receptor α1 subunit (IL-13α1), is used in the treatment of moderate to severe atopic dermatitis (AD).

Atopic dermatitis is one of the most common skin diseases, with more than 200 million patients worldwide

▲ Mechanism of action of ASLAN004 (picture source: ASLANKO official website)

The results announced today showed that in addition to the primary endpoint, other key efficacy endpoints of the trial also showed significant improvement (p<0.

in particular:

In the revised intention-to-treat population (n=29), at the 8th week of treatment, patients in the ASLAN004 group had an average reduction in EASI of 65% from baseline (n=16), compared with 27% of patients in the placebo group (n=13) ( p=0.

69% of patients in the ASLAN004 group reached EASI-75, and 15% in the placebo group (p=0.

44% of patients in the ASLAN004 group achieved a score of 0 or 1 in the Investigator's Overall Assessment (IGA), compared with 15% in the placebo group (p=0.

In all 32 patients who completed at least 29 days of dosing, the EASI of ASLAN004 group was reduced by an average of 73% from baseline at week 8 (n=19), compared with 44% (n=13) in the placebo group (p= 0.

The specific results of the test are shown in the following table:

Picture source: reference [1]

Reference materials:

[1] ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis.

(The original text has been deleted)